Sun Pharma share price slips 2 per cent post settlement order by SEBI
Sun Pharma share price slips 2 per cent post settlement order by SEBI

Sun Pharma share price slips 2 per cent post settlement order by SEBI

Anthony Fernandes Article rating: 4.4

The shares of the drug manufacturer, Sun Pharmaceutical Industries Ltd had initially touched its 52-week high during the early trade on Friday but soon, slipped by almost 2 per cent after Securities & Exchange Board of India (SEBI) issued an order for settling charges made by a whistleblower.  

Alembic Pharma subsidiary secures USFDA accelerated approval for its partnered asset, Umbralisib
Alembic Pharma subsidiary secures USFDA accelerated approval for its partnered asset, Umbralisib

Alembic Pharma subsidiary secures USFDA accelerated approval for its partnered asset, Umbralisib

Anthony Fernandes Article rating: 5.0

Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company and subsidiary of Alembic Pharma announced that its novel next-generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics, has secured USFDA accelerated approval.  

Ahluwalia Contracts secures order worth Rs. 522 crore
Ahluwalia Contracts secures order worth Rs. 522 crore

Ahluwalia Contracts secures order worth Rs. 522 crore

Amir Shaikh Article rating: 5.0

Ahluwalia Contracts informed the bourses that it has secured orders worth Rs. 521.71 crores. In today’s trading session, the stock of Ahluwalia Contracts was trading flat. The stock opened at Rs. 304.5 and settled for the day at Rs. 303 per share.

NBCC gains 5 per cent on bagging new order
NBCC gains 5 per cent on bagging new order

NBCC gains 5 per cent on bagging new order

Shohini Nath Article rating: 5.0

NBCC has received a Letter of Award (LoA) of work from Indian Institute of Management (IIM) Sambalpur. The shares of the company rose 5.7 per cent intraday on the BSE.


Reliance and Aramco ink mega deal
Reliance and Aramco ink mega deal

Reliance and Aramco ink mega deal

Shohini Nath Article rating: 3.5

Saudi Aramco and Reliance Industries Limited (RIL) have agreed to a non-binding Letter of Intent (LoI).


RSS
1345678910Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR